Observation of liver indexes in patients with relapsed/refractory multiple myeloma treated with CAR-T-cells based on BCMA  

作　　者：孙乾 SUN Qian(Hematol Instit,Xuzhou Med Univ,Hematol Dept,Affil Hosp,Xuzhou Med Univ,Jiangsu Prov Key Lab,Bone Marrow Stem Cell,Xuzhou 221002)

机构地区：[1]Hematol Instit,Xuzhou Med Univ,Hematol Dept,Affil Hosp,Xuzhou Med Univ,Jiangsu Prov Key Lab,Bone Marrow Stem Cell,Xuzhou 221002

出　　处：《China Medical Abstracts(Internal Medicine)》2024年第1期58-58,共1页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To observe the characteristics of the evolution of liver indexes in patients with relapsed/refractory multiple myeloma (RRMM) treated with CART-cells based on BCMA.Methods Retrospective analysis was performed on patients with RRMM who received an infusion of anti-BCMA CAR-T-cells and anti-BCMA combined with anti-CD 19 CAR-T-cells at our center between June 1,2019,and February 28,2023.

关 键 词：BCMA CAR LIVER 

分 类 号：R733.3[医药卫生—肿瘤]